• WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS
  • WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS

(Bersacapavir) In Participants With Moderate Hepatic Impairment.

Science
ShareTwitterFacebookXingLinkedin
clinical pharmacologyhepatic impairmenthepatitis Bviral hepatiti

You May Also Like

Science 16. November 2023
Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults
Science 16. November 2023
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
Science 25. Mai 2023
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
QUICK LINKS
  • WE ARE
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • MANAGEMENT
  • EARLY PHASE
    • First-in-human
    • Cardiac safety
    • Infusion & injection
    • Inhalation
    • Pharmacology
    • Interaction
    • Consultancy
    • Medical Writing
    • Data Management
.
  • PATIENT TRIALS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
  • WORK WITH US
EXPERTISE
  • Consultancy
  • Medical Writing
  • Early Phase
FACILITIES
  • Berlin
  • Kiel
  • Mannheim
  • Wuppertal
FÜR PROBANDEN
  • ÜBER STUDIEN
  • AN STUDIEN TEILNEHMEN
  • www.probandeninfo.de
LEGAL
  • PRIVACY
  • IMPRINT
  • DISCLAIMER
  • —
  • Career
    • CURRENT JOB
    • OPPORTUNITIES
Copyright © 2023 CRS. Experts. Early Phase. All rights reserved.